Biohaven Ltd. BHVN
Analyst Ratings
- Consensus
- Hold — 5 Buy · 5 Hold · 1 Sell (11 analysts)
- Avg. Price Target
- $15.70 (+5.4% upside)
Key Stats
- Today's Range
- $14.22 – $14.94
- 50-Day Range
- $11.93 – $18.24
- 52-Week Range
- $7.48 – $18.57
- Volume
- 1.36 million shs
- Average Volume
- 3.39 million shs
- Market Cap
- $2.15 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -2.67
- Price / Sales
- 2.50
Short Interest
- Short Interest
- 0.79%
- Days to Cover
- 4.13
Financials (TTM)
- Revenue
- $859.68 million
- Net Income
- $-930,691,000
- Net Margin
- -108.26%
- Return on Equity
- 115.53%
- Debt-to-Equity
- -0.95
About Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Related Stocks
Compare head-to-head: BHVN vs LLY·BHVN vs JNJ·BHVN vs ABBV·BHVN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.